Erlotinib + Docetaxel
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Timeline
Aug 1, 2012 → Dec 1, 2015
NCT ID
NCT01652469About Erlotinib + Docetaxel
Erlotinib + Docetaxel is a phase 3 stage product being developed by Biodesix for Carcinoma, Non-Small-Cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT01652469. Target conditions include Carcinoma, Non-Small-Cell Lung.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Non-Small-Cell Lung were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01652469 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung